Molecular insights into fosfomycin resistance in Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 5, 2017, Pages 1303-1309

  Ballestero Tellez M ^a,b,c   Docobo Perez F ^b,c,d   Portillo Calderon I ^a,b   Rodriguez Martinez J M ^b,c,d   Racero, L ^a   Ramos Guelfo, M S ^a   Blazquez J ^b,e   Rodriguez Bano J ^a,c,d   Pascual, A ^a,b,c,d  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

^e CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; ESCHERICHIA COLI PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRP GENE; CYAA GENE; ESCHERICHIA COLI; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENETIC ANALYSIS; GLPT GENE; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MURA GENE; NONHUMAN; PTSI GENE; UHPA GENE; UHPB GENE; UHPC GENE; UHPT GENE; DRUG EFFECTS; GENE; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FOSFOMYCIN; GENES, MDR; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 85020112041     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw573     Document Type: Article

References (20)

1. Falagas ME, Vouloumanou EK, Samonis G et al. Fosfomycin. Clin Microbiol Rev 2016; 29: 321-47
2. Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol 2016; 2016: 2082693
3. Veve MP, Wagner JL, Kenney RM et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum b-lactamase urinary tract infections. Int J Antimicrob Agents 2016; 48: 56-60
4. Marger MD, Saier MH. A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport. Trends Biochem Sci 1993; 18: 13-20
5. Ambudkar SV, Larson TJ, Maloney PC. Reconstitution of sugar phosphate transport systems of Escherichia coli. JBiolChem1986; 261: 9083-6
6. Kadner RJ, Murphy GP, Stephens CM. Two mechanisms for growth inhibition by elevated transport of sugar phosphates in Escherichia coli. J Gen Microbiol 1992; 138: 2007-14
7. Merkel TJ, Nelson DM, Brauer CL et al. Promoter elements required for positive control of transcription of the Escherichia coli uhpT gene. J Bacteriol 1992; 174: 2763-70
8. Yang B, Gerhardt SG, Larson TJ. Action at a distance for glp repressor control of glpTQ transcription in Escherichia coli K-12. MolMicrobiol 1997; 24: 511-21
9. Görke B, Stülke J. Carbon catabolite repression in bacteria: many ways to make themost out of nutrients. Nat RevMicrobiol 2008; 6: 613-24
10. Nilsson AI, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-8
11. Takahata S, Ida T, Hiraishi T et al. Molecularmechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2010; 35: 333-7
12. Tseng S-P, Wang S-F, Kuo C-Y et al. Characterization of fosfomycin resistant extended-spectrum b-lactamase-producing Escherichia coli isolates from human and pig in Taiwan. PLoS One 2015; 10: e0135864
13. Li Y, Zheng B, Li Y et al. Antimicrobial susceptibility andmolecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China. PLoS One 2015; 10: e0135269
14. Baba T, Ara T, Hasegawa M et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2006; 2: 2006. 0008
15. Cherepanov PP, Wackernagel W. Gene disruption in Escherichia coli: TcR and KmR cassetteswith the option of Flp-catalyzed excision of the antibioticresistance determinant. Gene 1995; 158: 9-14
16. Thomason LC, Costantino N, Court DL. E. coli genome manipulation by P1 transduction. Curr Protoc Mol Biol 2007; 79: 1. 17. 1-1. 17. 8
17. Pfausler B, Spiss H, Dittrich P et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004; 53: 848-52
18. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement M100-S25. CLSI, Wayne, PA, USA, 2015
19. Docobo-Pérez F, Drusano GL, Johnson A et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother 2015; 59: 5602-10
20. VanScoy BD, McCauley J, Ellis-Grosse EJ et al. Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model. Antimicrob Agents Chemother 2015; 59: 7170-7